3-iodobenzylguanidine has been researched along with dexmedetomidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, HW; Jung, KH; Lee, EJ; Lee, KH; Paik, JY; Park, JW | 1 |
| DuBois, SG; Gustafson, C; Hawkins, R; Lee, JS; Matthay, K; Roy-Burman, A; Wong, T; Wu, R | 1 |
| Batra, V; Elias, J; Makvandi, M; Maris, JM; Patel, N; Pryma, DA; Zuppa, AF | 1 |
3 other study(ies) available for 3-iodobenzylguanidine and dexmedetomidine
| Article | Year |
|---|---|
α2-Adrenergic agonists including xylazine and dexmedetomidine inhibit norepinephrine transporter function in SK-N-SH cells.
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-2 Receptor Agonists; Cell Line, Tumor; Dexmedetomidine; Fluoxetine; Humans; Iodine Radioisotopes; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Receptors, Adrenergic, alpha-2; Xylazine | 2013 |
Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma.
Topics: 3-Iodobenzylguanidine; Child; Child, Preschool; Conscious Sedation; Dexmedetomidine; Female; Humans; Hypnotics and Sedatives; Infant; Infusions, Intravenous; Male; Neuroblastoma; Pyridazines; Radiopharmaceuticals | 2016 |
Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Topics: 3-Iodobenzylguanidine; Dexmedetomidine; Humans; Hypnotics and Sedatives; Iodine Radioisotopes; Neuroblastoma; Radiopharmaceuticals; Tissue Distribution; Tumor Cells, Cultured | 2017 |